Sorafenib

From OncoWiki
Jump to: navigation, search

Drug information

Regimen

Hepatocellular carcinoma

  • Sorafenib (Nexavar) 400 mg po bid

References

Llovet J et al.Sorafenib improves survival in advanced hepatocellular carcinoma (HCC): results of a phase III randomized placebo-controlled trial (SHARP trial). 2007 ASCO annual meeting. Abstract LBA1

Kidney Renal Cell Cancer

  • Sorafenib (Nexavar) 400 mg po bid

Approved by FDA on 12/20/2005

References

Sablin MP et al. Sequential use of sorafenib and sunitinib in renal cancer: retrospective analysis in 90 patients. 2007 ASCO annual meeting. Abstract 5038

Amato RJ et al. A phase II trial of intra-patient dose-escalated sorafenib in patients (pts) with metastatic renal cell cancer (MRCC). 2007 ASCO annual meeting. Abstract 5026

Szczylik C et al. Randomized phase II trial of first-line treatment with sorafenib versus interferon in patients with advanced renal cell carcinoma: final results. 2007 ASCO annual meeting. Abstract 5025

Escudier B et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Eng J Med 2007; 356:125

Ratain MJ et al. Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma. J Clin Oncol 2006; 24:2505